Exploring Targeted Degradation Strategy for Oncogenic KRASG12C.

Volume: 27, Issue: 1, Pages: 19
Published: Jan 16, 2020
Abstract
Summary null null KRAS is the most frequently mutated oncogene found in pancreatic, colorectal, and lung cancers. Although it has been challenging to identify targeted therapies for cancers harboring KRAS mutations, KRASG12C can be targeted by small-molecule inhibitors that form covalent bonds with cysteine 12 (C12). Here, we designed a library of C12-directed covalent degrader molecules (PROTACs) and subjected them to a rigorous evaluation...
Paper Details
Title
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C.
Published Date
Jan 16, 2020
Volume
27
Issue
1
Pages
19
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.